Emily S. Riser

Board Certified Neurologist with extensive clinical and research experience.

• Tanner Center for MS, Medical Director
• Comprehensive Member of the Consortium of MS Centers
• Comprehensive MS Center, National MS Society
• American Academy of Neurology
• American Society of Neurorehabilitation, Past Member, Board
• American Society of Neuroimaging
• National MS Society, Past Member of Board of Trustees, Alabama

TG Therapeutics

• American Board of Neurology and Psychiatry, 1990
• American Society of Neurorehabilitation, 1996
• American Academy of PM&R Spinal Cord Medicine, 2000
• United Council of Neurologic Subspecialties Neuroimaging, 2011

• Assistant Professor, University of Alabama Department of Neurology, 1996-2000
• Clinical Associate Professor, Department of Neurology, University of Alabama, 2014 - present
• Clinical Associate Professor, University of Alabama Department of Physical Therapy, 2016 - present

• A Model for Facilitating Rehabilitative Care for Persons with Multiple Sclerosis, Coauthor, CMSC, 2011
• Newly Diagnosed: Emerging Model in MS Care, First Author, CMSC, 2012
• Assessing Relapse in Multiple Sclerosis (ARMS) questionnaire: Initial pilot data, 2013
• Profile of a Newly Diagnosed Person with MS, First Author, CMSC, 2013
• Bladder Dysfunction and Disability in Persons Newly Diagnosed with MS, Coauthor, CMSC, 2014
• Tanner Health Miles: Walking and Talking Multiple Sclerosis, Coauthor, CMSC, 2015
• MSCARES: Therapy Protocol for Persons with Multiple Sclerosis, Coauthor, CMSC, 2016
• Comparative and Effectiveness Trial between a Clinic and a Home Based Neurorehabilitation/Exercise Intervention for Adults with Multiple Sclerosis – TEAMS, Coauthor, ACRM, 2017
• A Multilevel Patient Engagement Model for Recruiting Hard to Reach Populations into Training Exercise Programs, Coauthor, ACSM Conference, 2018
• Convergent and Divergent Validity of Timed 25 – Foot Walk Benchmarks in Persons with Multiple Sclerosis, Coauthor, ECTRIMS, 2019
• Lymphocyte Reconstitution ~ 3 Months After Dimethyl Fumarate Discontinuation in Lymphopenia Patients, Coauthor, The 31st Annual Meeting of the Japanese Society for Neuroimmunology, 2019
• Baseline Demographics, Disease Characteristics, and Clinical Measures of Patients with Relapsing MS in ENLIGHTEN: A Phase 3b Study of Ozanimod on Cognitive Processing Speed, Coauthor, CMSC, 2022
• Supporting Successful Recruitment in a Randomized Control Trial comparing clinic and home-based exercise among adults with multiple sclerosis, Coauthor, Research and Engagement, BMC, 2022
• Baseline Cognition and Magnetic Resonance Imaging Measures of Patients with Relapsing Multiple Sclerosis in ENLIGHTEN: A Study of the effect of Ozanimod on Cognitive Processing Speed, Coauthor, ACTRIMS, 2023
• Baseline Relationships between Measures of Cognitive Function and Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis in Enlighten: A Phase 3b Study of Ozanimod, Coauthor, CMSC, 2023
• The MS-LINK Outcomes Study Cohort: Study design and a descriptive analysis of baseline key PRO’s, disease, and sociodemographic characteristics, Coauthor, AAN, 2023
• Switching from Rituximab to Eculizumab in patients with AQP4+ NMOSD in the United States: Impact on hospitalizations and comorbidities, Coauthor, ECTRIMS, 2023
• Late-breaking Abstract Poster Correlations between patient-reported and clinical outcomes in patients with multiple sclerosis in the MS-LINK Outcomes Study cohort, Coauthor, ECTRIMS, 2023
• Change in thalamic nuclei volumes and thalamic connectivity after 1 year of ozanimod use in patients with early relapsing multiple sclerosis: an interim analysis of the ENLIGHTEN study, Coauthor, ECTRIMS, 2023
• Stable Medulla Oblongata Volume, Lateral Ventricular Volume, and Physical Disability during 1 Year of Ozanimod Use for Early Relapsing MS, Coauthor, CMSC, 2024
• Switching From Rituximab to Eculizumab in Patients with Anti–Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder in the United States: Impact on Hospitalizations and Comorbidities, Coauthor, CMSC, 2024
• Efficacy and Tolerability of Ublituximab after Transitioning from a Different Disease-Modifying Therapy: Updates from the ENHANCE Study, Coauthor, ECTRIMS, 2024
• Efficacy and safety of Ozanimod in patients with early relapsing multiple sclerosis: year 1 interim analysis of the ENLIGHTEN study, Coauthor
• Efficacy and Safety of a Modified Ublituximab Regimen (ENHANCE), Coauthor, AAN, 2025
• MS-LINK Outcomes Study: Study Design and Descriptive Analyses of Patient-Reported Outcomes, Disease and Sociodemographic Characteristics, Coauthor, CMSC, 2025
• Relationship between cognitive performance and brain volume outcomes in patients with early relapsing multiple sclerosis in the ENLIGHTEN ozanimod open-label study, Coauthor, CMSC, 2025

Roche VERISMO (BA39731), An Observational Study of Ocrelizumab-Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies,

 Roche GAVOTTE (BN42083), A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis, Roche MUSETTE (BN42082), A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled, Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis, Corvitas SPHERES NMOSD-750, Registry for Neuromyelitis Optica Spectrum Disorder, Novartis SOSTOS (COMB157GUS09), A Phase IV Randomized, Open Label, Multicenter, Active-comparator Study to Assess Efficacy, Safety, and Tolerability of Ofatumumab 20mg SC Monthly versus Continued Current Treatment in Relapsing Remitting Multiple Sclerosis after Elevation of Serum Neurofilament Light Levels, Roche FENHANCE (GN41851), A Phase III Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Relapsing Multiple Sclerosis, Roche FENTREPID (GN41791), A Phase III Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Participants with Primary Progressive Multiple Sclerosis, TG Therapeutics ENHANCE (TG1101-RMS401), Evaluating the Maintenance of Efficacy when Transitioning from current anti-CD therapy to Ublituximab, Sanofi FREXALT (EFC17919), Phase III Study to Evaluate the Safety and Efficacy of Frexalimab in adults with Relapsing form of Multiple Sclerosis, Sanofi FREVIVA (EFC175040), Phase III Study evaluating the Safety of treatment with Frexalimab in adults with nonrelapsing secondary progressive multiple sclerosis, TG Therapeutics ENABLE (TG1101-RM406), Real World Experience with Briumvi treated patients: a Longitudinal registry study., Novartis FILIOS (COMB157Q12301), An Open Label, randomized, parallel group, non-inferiority study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new maintenance dosing regimen of ofatumumab, followed by extended treatment in participants with relapsing multiple sclerosis., Biogen ACT (C-865), A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX in Combination with Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects with Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy, 2013, Biogen: A Safety Study of Combination Treatment with Avonex and Zocor in Relapsing Remitting Multiple Sclerosis, 2005, Teva NABS COUNT (PM028), A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing Antibody Testing on Treatment Patterns versus Usual Care in High-Dose Interferon Treated Subjects, 2006, Genzyme CARE-MS II (CAMMS32400507), A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Relapsed on Therapy, 2007, Biogen TYGRIS (101-MS-402), TYGRIS: Tysabri Global Observational Program in Safety, 2007, Teva BRAVO (MS-LAQ-302), A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and of a Reference Arm of Interferon B-1a (Avonex), in a Rater-blinded Design, 2008, Teva BRAVO EXTENSION (MS-LAQ-302E), A Multinational, Multicenter, Open-Label, Single-Assignment Extension of the MS-LAQ-302 (BRAVO) Study, To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects with Relapsing Multiple Sclerosis, 2010, Novartis EPOC (CFTY720DUS01), A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety, and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy, 2020, Teva GALA (MS-GA-301), A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo In a Double-Blind Design, 2010, Biogen STRATIFY-2 (101JC402), JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri, 2010, Mallinckrodt ARMS (QSC02-ARMS-01), Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire – A Phase 4 Pilot Study, 2011, Avanir Pharmaceuticals PRISM I, Pseudobulbar Affect Registration Series (PRISM I) Study, 2012, Biogen STRIVE (101-MS-407), A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients, 2012, Sanofi TERI PRO (LPS13567), A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients, 2013, Questor Pharmaceuticals (TCFMS: QP1-2013), Comprehensive Analysis of Relapse in Multiple Sclerosis, 2013, Biogen ENHANCE (218-MS-305), A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB014) 10mg, Administered Twice Daily in Subjects with Multiple Sclerosis, 2014, Biogen STRATEGY (109-MS-412), A Multicenter, Retrospective, Observational Study Evaluating Real-World Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis Patients Who Transition from Tysabri (Natalizumab) to Tecfidera (Dimethyl Fumarate), 2014, Biogen ADHERE (109-MS-413), A Multicenter, Open-Label, Phase IV Study to Evaluate whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera (Delayed-Release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients, 2015, Biogen REALIZE, A Retrospective, Multi-Center, Observational Study to Assess the Effect of Tecfidera Delayed-Release Capsules on Lymphocyte Subsets in Subjects with Relapsing Forms of Multiple Sclerosis, 2015, Mallinckrodt STAR (MNK14130050), A Prospective Observational Registry of H.P. Acthar Gel for the Treatment of Multiple Sclerosis Relapse, 2015, Biogen EFFECT (109MS421), A multicenter, global, retrospective, observational (chart-review) study to characterize real-world clinical outcomes in patients with relapsing-remitting multiple sclerosis treated with disease-modifying therapies (Tecfidera, Copaxone, Aubagio, or Gilenya), 2016, IMS Health PROTRACT (MS200136_0037), Patient Real-World Clinical, Neurological, Tolerability, And Safety Outcomes for Tecfidera and Rebif: A Retrospective Study, 2016, Novartis FLUENT (CFTY720DUS40), A 12-Month, Prospective, Multicenter, Two-Cohort, Nonrandomized, Open-Label Study in Adult Patients with Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5 mg Fingolimod (FTY720), 2017, Novartis PASSAGE (FTY2403), A Phase IV Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy, 2011, Biogen POP (105MS401), Plegridy (peginterferon β-1a) A Phase IV Real World Effectiveness and Safety Observational Program, 2014, PCORI TEAMS (HSRP20164136), Comparative Effectiveness Trial between a Clinic- and Home-Based Complementary and Alternative Medicine Telerehabilitation Intervention for Adults with Multiple Sclerosis, 2016, Biogen NOVA (101MS329), A Phase III Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects with Relapsing-Remitting Multiple Sclerosis Switching from Treatment with 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment, 2018, Biogen ESTEEM (109MS401), A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Biogen, 2018, Novartis EXCHANGE (CBAF312AUS02), A Phase III Study Exploring the Safety and Tolerability of Conversion from Oral or Injectable Disease Modifying Therapies to Dose Titrated Oral Siponimod in Patients with Advancing Forms of Relapsing Multiple Sclerosis: A 6-Month Open-Label, Multicenter Phase IIIb Study, 2019, Mapi Pharma MAPI GA DEPOT (MPIGADP3-GADPT3), A Phase III Multinational, Multicenter, Randomized, Phase III, Double Blind, Parallel Group, Placebo Controlled Study in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks, 2019, Novartis VACCINE STUDY (COMB157GUS12), A Phase IV Open Label Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated with Ofatumumab., 2022-ongoing, Novartis ENLIGHTEN (RPC-1063-MS-001), A Phase III Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063)., 2020-ongoing, Novartis OLIKOS (COMB157GUS07), A Phase IV Single-Arm, Prospective, Multicenter Study to Explore Maintained Efficacy with Ofatumumab Therapy in Patients with Relapsing Multiple Sclerosis who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (CD20 mAb) Therapy., 2021-ongoing, EMD Serono MS Link Outcomes Study, A Comprehensive Prospective Longitudinal Assessment of Patient and Clinical Reported Outcomes in Multiple Sclerosis Patients across North America, Novartis SOSTOS (COMB157GUS09), A Phase IV Randomized, Open Label, Multicenter, Active-comparator Study to Assess Efficacy, Safety, and Tolerability of Ofatumumab 20mg SC Monthly versus Continued Current Treatment in Relapsing Remitting Multiple Sclerosis after Elevation of Serum Neurofilament Light Levels